Welcome to Neptune, NENs with PRRT.

Neuroendocrine neoplasms (NENs) are increasingly prevalent, posing significant management challenges due to their diverse origins and heterogeneity. Progression-free survival vary significantly across different NEN subtypes, reflecting the complex nature of these tumors. Despite this variability, certain shared molecular characteristics, such as somatostatin receptor expression, enable targeted treatments like somatostatin analogs and peptide receptor radionuclide therapy (PRRT), with Lutetium-177 (177Lu-DOTATATE) being particularly notable. However, patient outcomes can vary considerably, emphasizing the need for predictive tools to inform better treatment decisions in advanced NENs. This calculator aims to estimate patient outcomes using real-world data and clinical factors.